Lilly and Roche learn from Biogen’s mistakes
As Biogen continues to provide a case study in how not to launch a drug, Lilly and Roche insist the focus must remain on pivotal readouts.
Argenx’s independent streak approaches its biggest test
Armed with the first approval for an FcRn antagonist, the Belgian company’s chief executive remains convinced by a solo strategy.
EU steers clear of Aduhelm as a bigger headache threatens
Aduhelm’s likely EU rejection comes amid a key senior executive departure and federal inquiry, and the drug now faces a crucial Medicare decision.
Astellas readies roxadustat for launch
But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
